Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation – a protocol for a randomized controlled pilot study

Introduction

Traditionally, fever has been treated because its metabolic costs were felt to outweigh its potential physiologic benefit in an already stressed host.[1] However, increasing data suggest that fever may be a protective adaptive response that should be allowed to run its course under most circumstances.[2, 3] Higher early fever is associated with a lower risk of death among patients with an ICU admission diagnosis of infection.[4, 5] Fever may enhance immune-cell function,[6, 7] inhibit pathogen growth,[8-10] and increase the activity of antimicrobial drugs.[11] Fever potentially benefits infected patients via multiple mechanisms; in vitro and animal studies have shown that elevated temperatures augment immune function, increase production of protective heat shock proteins, directly inhibit microorganism growth, reduce viral replication, and enhance antibiotic effectiveness.[3, 12] More rapid recoveries are observed from chickenpox,[13] malaria,[14] and rhinovirus [15] infections with avoidance of antipyretic medication, and many innate and adaptive immunological processes are accelerated by fever.[16-18]

Randomized controlled trials have consistently failed to find benefits to treating fever of infectious etiology.[16, 19-24] A retrospective cohort study evaluating 1,264 patients requiring mechanical ventilation found that high fever (≥39.5°C) was associated with increased risk for mortality in mechanically ventilated patients; however, in patients with sepsis, moderate fever (38.3°C-39.4°C) was protective, and antipyretic medication was not associated with changes in outcome.[25] As recently as the 1910’s, the "malaria fever cure” (inducing fever to treat a range of conditions, an approach known as “pyrotherapy”) was widespread, with the originator of the idea receiving the Nobel Prize in Medicine or Physiology in 1927.[26, 27] Currently, the UK National Institute for Health and Care Excellence (NICE) recommend not using antipyretic agents “with the sole aim of reducing body temperature in children with fever.”[16, 28] Actively inducing hyperthermia by directly heating the body has been used in cancer treatment, with minimal adverse effects.[29-32] Hyperthermia has been found to have positive impacts on the immune system, causing increased levels of heat-shock proteins,[33, 34] which are directly related to antigen presentation and crosspresentation, activation of macrophages and lymphocytes, and activation and maturation of dendritic cells.[35] A pilot study of external warming of septic patients (ClinicalTrials.gov Identifier: NCT02706275) has recently been completed.

Many viruses replicate more robustly at cooler temperatures, such as those found in the nasal cavity (33-35°C) than at warmer core body temperature (37°C).[36-40] Coronavirus disease 2019 (COVID-19) and its causative virus (SARS-CoV-2) may behave similarly.[41] Simulations of the receptor binding domain (RBD) of SARS-CoV-2 found high flexibility near the binding site, suggesting that the RBD will have a high entropy penalty upon binding angiotensin-converting enzyme II (ACE2), and that consequently, the virus may be more temperature-sensitive in terms of human infection than other coronaviruses.[42] Notably, fever has often abated by the time a COVID-19 patient requires mechanical ventilation.[43] The aim of this study is to determine the effect of active core warming patients diagnosed with COVID-19 and undergoing mechanical ventilation. We hypothesize that active core warming will reduce the severity of acute respiratory distress syndrome, reduce the duration of mechanical ventilation, and improve survival compared to standard of care.

Methods

This is a single-center pilot study to evaluate if core warming improves respiratory physiology of mechanically ventilated patients with COVID-19, allowing earlier weaning from ventilation, and greater overall survival. This prospective, randomized study will include 20 patients diagnosed with COVID-19, and undergoing mechanical ventilation for the treatment of respiratory failure. Patients will be randomized in a 1:1 fashion with 10 patients (Group A) randomized to undergo core warming with an esophageal heat transfer device, and the other 10 patients (Group B) serving as the control group. Patients randomized to Group A will have the esophageal heat transfer device placed in the ICU or other clinical environment in which they are being treated after enrollment and provision of informed consent from appropriate surrogate or legally authorized representative.

Screening

Subjects will be recruited from the ICU or other clinical environment in which they are being treated (Emergency Department, step-down unit, etc.). Patients will be identified by the PI or other study investigators/coordinators as available. All patients without a DNR order with a diagnosis of COVID-19 and meeting inclusion criteria will be eligible for screening for any exclusion criteria. Written informed consent for the research study will be obtained from patient’s surrogate or legally authorized representative prior to enrollment.

Study Intervention and Monitoring

Participants who have a signed research study consent form (via surrogate or legally authorized representative) will be randomized in a 1:1 fashion to core warming or to standard of care (standard temperature management and treatment). The esophageal heat transfer device will be used according to FDA 510(k) labeling (for patient warming). Patient temperature measurements will be collected for both the device and standard-of-care arms during the study period (up to 3 days). Device placement will be performed using standard protocol per instructions for use. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. All patients will have usual standard of care labs, vital signs, and imaging for patients in critical condition undergoing mechanical ventilation in the ICU. Specific parameters to be measured include PaO2 at regular intervals appropriate for patients undergoing mechanical ventilation, and FiO2 at the time of obtaining blood gases for PaO2 measurement, to allow calculation of P/F ratio.

Study Endpoints

The purpose of this pilot study is to determine if core warming reduces the severity of acute respiratory distress syndrome as measured by PaO2/FiO2 ratio 0, 24, 48, and 72 hours after initiation.

Primary Study Endpoints

The primary endpoint of this study will be:

1. PaO2/FiO2 ratio

Secondary study endpoints include:

1. Duration of mechanical ventilation

2. Duration of ICU and hospital stay

3. Amount of viral shedding

4. Patient mortality

Inclusion Criteria

1. Patients above the age of 18 years old.

2. Patients with a diagnosis of COVID-19 on mechanical ventilation.

3. Patient maximum baseline temperature (within previous 12 hours) < 38.3°C.

4. Patients must have a surrogate or legally authorized representative able to understand and critically review the informed consent form.

Exclusion Criteria

1. Patients without surrogate or legally authorized representative able to provide informed consent.

2. Patients with contraindication to core warming using an esophageal core warming device.

3. Patients known to be pregnant.

4. Patients with <40 kg of body mass.

5. Patients with DNR status.

6. Patients with acute stroke, post-cardiac arrest, or multiple sclerosis.

Subject Recruitment

Subjects will be recruited from the ICU or other clinical environment in which they are being treated (Emergency Department, step-down unit, etc.). Patients will be identified by the PI or other study investigators/coordinators as available. All patients without a DNR order with a diagnosis of COVID-19 and meeting inclusion criteria will be eligible for screening for any exclusion criteria. Written informed consent for the research study will be obtained from patient’s surrogate or legally authorized representative prior to enrollment. If a patient enrolled in the study gains the capacity to consent for him/herself while the study is in progress, the patient will be approached by a study team member and the consent document will be presented directly to the patient. All questions the patient might have will be answered. The patient will be given the opportunity to either withdraw from the study or sign the consent form. The patient will be informed that his or her decision to withdraw from the study will not affect his or her medical care

Duration of Study Participation

Participants will be involved for approximately 1 month, including screening, treatment, and follow-up. After consent, patient participation in the intervention phase will last up to 3 days for active treatment. The follow up for determination of outcome and duration of mechanical ventilation will occur at 1-month post-treatment. Additional data will be collected via chart review.

Total Number of Subjects and Sites

This single-site study aims to recruit and randomize 20 patients. It is expected that up to 30 subjects may be consented in order to produce 20 randomized & evaluable subjects.

Core temperature modulation

Core temperature control and warming will be performed with a commercially available esophageal heat exchange device (ensoETM, Attune Medical, Chicago, IL). This device is currently used world-wide for various patient temperature management goals, including post-cardiac arrest therapeutic hypothermia, [44-47] warming of burn patients,[48] warming general surgical patients,[49] cooling traumatic brain injury,[50] cooling heat stroke,[51] and the treatment of central fever.[52, 53] The device is a multi-chambered silicone tube placed in the esophagus and connected to a heat exchanger to provide heat transfer to or from a patient (video available at https://vimeo.com/306506411). Modulation and control of the patient’s temperature is achieved by adjusting setpoint on the external heat exchanger, which in turn controls the circulating water temperature. Two lumens of the device connect to the external heat exchanger, while a third central lumen provides stomach access for gastric decompression or tube feeding. It is a single-use, disposable, non-implantable device with an intended duration of use of 72 hours or less.

Intervention Regimen

Patients who are randomized to core warming will have the esophageal heat transfer device placed in the ICU or other treatment area where patient is undergoing mechanical ventilation. The device will remain in place until the study is completed (24-72 hours). The device will be set to 42°C for the duration of the study period. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.[41] If patient temperature increases above this range and reaches 40°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature. Patient temperature will be followed at intervals per standard of care in the intensive-care setting for mechanically ventilated patients (typically hourly).

Blinding

Due to the nature of this study, the physicians will not be blinded to the randomization assignment, however participants will be blinded. Once a subject is randomized, the research team will receive the randomization assignment (core warming or standard of care) and proceed with the procedures per the assignment.

Sample Size and Power Determination

Based on a prior study in patients with sepsis, a maximum temperature of 38.3°C to 39.4°C was associated with survival (aHR 0.61 [95% CI, 0.39-0.99]).[29] However, the effect of warming specific to COVID-19 patients remains uncertain, and as such, we are unable to accurately perform a power calculation for this pilot study. We believe that a total of 10 patients for each group will be required to yield the necessary pilot data to make an appropriate conclusion regarding the potential utility of core warming in improving pulmonary physiology, reducing mechanical ventilation duration, and increasing patient survival. It is anticipated that data from this pilot study can be used for planning future larger studies.

Statistical Methods

We will utilize standard measures to report outcomes and measure differences between groups. Specifically, we will use descriptive statistics, including mean (standard deviation) and median (interquartile range). Normality will be assessed using histograms and the Kolmogorov–Smirnov test. Categorical variables will be compared using the chi-squared test or Fisher exact test. Continuous variables will be compared using the independent samples t or Mann–Whitney U test.

Efficacy Analysis

This is a pilot study to determine the potential role of core warming during COVID-19 treatment.

Interim Safety Analysis

All subjects entered into the study and randomized at the baseline timepoint will have detailed information collected on adverse events for the overall study safety analysis. An interim safety analysis will be performed after the first 10 subjects are enrolled in the trial. At this time the safety and tolerability of the study device will be assessed and if deemed safe and appropriate, enrollment will continue to 20 subjects.

Subject Population for Analysis

All patients enrolled, randomized to a study arm, and completed in the study will be included for analysis.

Conclusion

We describe, before the initiation of any data collection, our approach to obtaining and analyzing data from a pilot randomized-controlled trial of core warming patients undergoing mechanical ventilation due to COVID-19. We anticipate this framework will enhance the utility of the reported results and provide a solid basis from which to design and execute subsequent investigations.

Author contributions

NB, AD, RB, EK: conceptualization, design, drafting, and review of protocol and manuscript; EG, KG: protocol refinement, manuscript review and critical revision.

COI: EK declares equity interest in Attune Medical.